<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In the Bypass Angioplasty Revascularization Investigation 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> (BARI 2D) trial, an initial strategy of coronary revascularization and optimal medical treatment (REV) compared with an initial optimal medical treatment with the option of subsequent revascularization (MED) did not reduce <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality or the composite of cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and stable <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the same population, we tested whether the REV strategy was superior to the MED strategy in preventing worsening and new <z:mp ids='MP_0006112'>angina</z:mp> and subsequent coronary revascularizations </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Among the 2364 men and women (mean age, 62.4 years) with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, documented <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>, 1191 were randomized to the MED and 1173 to the REV strategy preselected in the percutaneous coronary intervention (796) and coronary artery bypass graft (377) strata </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with the MED strategy, the REV strategy at the 3-year follow-up had a lower rate of worsening <z:mp ids='MP_0006112'>angina</z:mp> (8% versus 13%; P&lt;0.001), new <z:mp ids='MP_0006112'>angina</z:mp> (37% versus 51%; P=0.001), and subsequent coronary revascularizations (18% versus 33%; P&lt;0.001) and a higher rate of <z:mp ids='MP_0006112'>angina</z:mp>-free status (66% versus 58%; P=0.003) </plain></SENT>
<SENT sid="4" pm="."><plain>The coronary artery bypass graft stratum patients were at higher risk than those in the percutaneous coronary intervention stratum, and had the greatest benefits from REV </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: In these patients, the REV strategy reduced the occurrence of worsening <z:mp ids='MP_0006112'>angina</z:mp>, new <z:mp ids='MP_0006112'>angina</z:mp>, and subsequent coronary revascularizations more than the MED strategy </plain></SENT>
<SENT sid="6" pm="."><plain>The symptomatic benefits were observed particularly for high-risk patients </plain></SENT>
<SENT sid="7" pm="."><plain>Clinical Trial Registration: URL: http://www.ClinicalTrials.gov </plain></SENT>
<SENT sid="8" pm="."><plain>Unique identifier: NCT00006305 </plain></SENT>
</text></document>